to theoretically compare each patient's individualized risk of requiring a future SUI procedure if one was not performed at the time of POP repair, compared to a surgical complication if a prophylactic SUI procedure was performed up front.
INTRODUCTION AND OBJECTIVES: Retropubic tension-free vaginal tape (TVT) is the gold standard treatment for female stress urinary incontinence (SUI). Concerns have been raised about the complications associated with midurethral mesh slings, and medical authorities in several countries have published warnings and even suspended their use. Transurethral injection of polyacrylamide hydrogel (PAHG) is a safe, minimally invasive alternative. However, the efficacy of this treatment in primary SUI is undefined.
We conducted a prospective, randomized, controlled, parallelgroup, non-inferiority trial comparing TVT and PAHG.
METHODS: A total of 224 women with primary SUI were randomized for TVT (n[111) or PAHG (n[113) treatment between September, 28, 2015, and March, 1, 2017 . Primary outcomes were patient satisfaction, effectiveness and complications at 1-year follow-up. Data were analysed with an intention-to-treat basis. The trial has been registered with ClinicalTrials.gov, number NCT02538991.
RESULTS: At 1-year follow-up the median (IQR 25-75 percentile) satisfaction score (0-100) for TVT was 99 and for PAHG 85 (p<001) and thus, PAHG did not meet the non-inferiority criteria. Similarly as with objective cure rates, the cough stress test was negative in 95% of TVT patients versus 66% of PAHG patients (p<001). However, most peri-operative complications (hematoma, bladder perforation or urinary retention) and all re-operations due to complications were associated with TVT. Furthermore, at 1-year erosions, pelvic /implantation site pain and difficulty to empty bladder were associated only with TVT.
CONCLUSIONS: Midurethral TVT-slings show better subjective and objective cure rates than PAHG in primary SUI. However, complications were mainly associated with TVT. Since the majority of PAHG treated women were also cured, primary SUI women can be offered PAHG as a safe first-line treatment, and subsequently TVT if unsuccessful. However, for women who expect to be completely cured by their initial treatment and are willing to accept the complication risks, TVT can be offered as the first line treatment.
Source of Funding: This study was funded by a Helsinki University Hospital research grant and an unrestricted grant from Contura. The funders of the study had no influence in the study design, data collection, data analysis, data interpretation, or writing of the report.
PD02-09 OUTCOMES OF MACROPLASTIQUE INJECTIONS FOR STRESS URINARY INCONTINENCE AFTER SUB-URETHRAL SLING REMOVAL
Dayron Rodriguez*, Deborah Hess, Feras Alhalabi, Timothy Carroll, Maude Carmel, Philippe Zimmern, Dallas, TX INTRODUCTION AND OBJECTIVES: Following suburethral sling removal (SSR) for synthetic sling complications, stress urinary incontinence (SUI) may occur in up to 59% of patients(1). Our study sought to evaluate outcomes following urethral Macroplastique (MPQ) injection in women with SUI following sub-urethral sling removal (SSR).
METHODS: Following Institutional Review Board approval, charts of non-neurogenic women with SUI secondary to intrinsic sphincter deficiency (ISD) after SSR who underwent MPQ injection were reviewed from a prospectively maintained database. Patients with follow-up less than 6 months were excluded. Baseline data included UDI-6 and VAS Quality of Life (QoL) Questionnaire scores. Patients were followed with repeat questionnaires and threedimensional ultrasound (3D US) evaluating volume of MPQ. Success following MPQ was defined as a composite score of self-reported improvement of more than 70%, usage of less than 2 pads/day, a UDI-6 question 3 score of 0-1, a VAS QoL score of less than 3, and no additional anti-incontinence therapy.
RESULTS: From 2011-2018, 70 women with mean age of 62.7 years met study criteria. At a mean follow-up of 46.4 AE 1.5 months, the success rate after a first MPQ injection was 41% (29/70). Of the 41 patients who failed initial injection, 27 underwent a repeat injection with a success rate of 52%. Therefore, the overall success rate for the entire cohort was 61% (43/70). Of the 13 patients who failed a second MPQ injection, 11 had stable MPQ volume on 3DUS (mean volume 8.43 AE 0.72ml). Four of these patients underwent autologous pubovaginal sling placement (PVS) to treat residual ISD with resolution of SUI. Of those who did not seek a second injection, 11
